First clinical experience with CDK4/6 inhibitors in breast cancer therapy

Cobec,Ionut Marcel; Moleriu,Lavinia; Moatar,Aurica Elisabeta; Rempen,Andreas

doi:10.3892/etm.2021.9954

First clinical experience with CDK4/6 inhibitors in breast cancer therapy

Authors:
- Ionut Marcel Cobec
- Lavinia Moleriu
- Aurica Elisabeta Moatar
- Andreas Rempen
View Affiliations

Affiliations: Clinic of Obstetrics and Gynecology, Diakonie‑Klinikum Schwäbisch Hall, D‑74523 Schwäbisch Hall, Germany, Department of Medical Informatics and Biostatistics, ‘Victor Babeș’ University of Medicine and Pharmacy, Timișoara, 300041 Timișoara, Romania, Clinic of Internal Medicine, Hohenloher Krankenhaus Öhringen, D‑74613 Öhringen, Germany
Published online on: March 22, 2021 https://doi.org/10.3892/etm.2021.9954
Article Number: 522

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

For hormone receptor‑positive, HER2‑negative breast cancer patients with metastatic or advanced disease, therapy with CDK4/6 inhibitors in addition to aromatase inhibitors (AIs) or to the estrogen receptor (ER) downregulator fulvestrant has resulted in an additional therapy option and a longer progression‑free survival. In the Gynecologic‑Oncology Clinic, Diakonie‑Klinikum Schwäbisch Hall, we followed and registered our initial clinical experience with CDK4/6 inhibitors, following the side effects and tumor response over two years since they were officially approved for general use in Germany. Differences were observed when palbociclib or ribociclib was used in combination with letrozole or anastrozole or fulvestrant. The dynamic side effects and tumor response under therapy with palbociclib or ribociclib were found to be comparable with the main reported data in the official drug information. The CDK4/6 inhibitors have an important and promising role in the therapy of breast cancer patients. Patient age and therapy duration do not influence the use of palbociclib or ribociclib, although it may be important which AI is used in combination with palbociclib.

View Figures

View References

1	World Health Organisation: Breast cancer. http://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/. Accessed September 15, 2020.
2	Ji F, Yang CQ, Li XL, Zhang LL, Yang M, Li JQ, Gao HF, Zhu T, Cheng MY, Li WP, et al: Risk of breast cancer-related death in women with a prior cancer. Aging (Albany NY). 12:5894–5906. 2020.PubMed/NCBI View Article : Google Scholar
3	Nadji M, Gomez-Fernandez C, Ganjei-Azar P and Morales AR: Immunohistochemistry of estrogen and progesterone receptors reconsidered: Experience with 5,993 breast cancers. Am J Clin Pathol. 123:21–27. 2005.PubMed/NCBI View Article : Google Scholar
4	Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012.PubMed/NCBI View Article : Google Scholar
5	Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY and Tobias JS: ATAC Trialists' Group. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 365:60–62. 2005.PubMed/NCBI View Article : Google Scholar
6	Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al: Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 375:1925–1936. 2016.PubMed/NCBI View Article : Google Scholar
7	Lundberg AS and Weinberg RA: Control of the cell cycle and apoptosis. Eur J Cancer. 35:531–539. 1999.PubMed/NCBI View Article : Google Scholar
8	Caldon CE, Daly RJ, Sutherland RL and Musgrove EA: Cell cycle control in breast cancer cells. J Cell Biochem. 97:261–274. 2006.PubMed/NCBI View Article : Google Scholar
9	Sherr CJ, Beach D and Shapiro GI: Targeting CDK4 and CDK6: From discovery to therapy. Cancer Discov. 6:353–367. 2016.PubMed/NCBI View Article : Google Scholar
10	Shapiro GI: Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 24:1770–1783. 2006.PubMed/NCBI View Article : Google Scholar
11	Ortega S, Malumbres M and Barbacid M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 1602:73–87. 2002.PubMed/NCBI View Article : Google Scholar
12	Gul A, Leyland-Jones B, Dey N and Pe P: A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: A genomic algorithm-based treatment approach. Am J Cancer Res. 8:2359–2376. 2018.PubMed/NCBI
13	Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, et al: ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 1:338–351. 2011.PubMed/NCBI View Article : Google Scholar
14	Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11(R77)2009.PubMed/NCBI View Article : Google Scholar
15	Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 16:25–35. 2015.PubMed/NCBI View Article : Google Scholar
16	Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, et al: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 375:1738–1748. 2016.PubMed/NCBI View Article : Google Scholar
17	Cersosimo RJ: Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women. Am J Health Syst Pharm. 76:1183–1202. 2019.PubMed/NCBI View Article : Google Scholar
18	Guo L, Hu Y, Chen X, Li Q, Wei B and Ma X: Safety and efficacy profile of cyclin-dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta-analysis of clinical trials. Cancer Med. 8:1389–1400. 2019.PubMed/NCBI View Article : Google Scholar
19	Pfizer Inc: IBRANCE 75/100/125 mg full prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx?id=2191. Accessed September 15, 2020.
20	Novartis Pharmaceuticals Corporation: Kisqali 200 mg prescribing information. https://www.novartis.us/sites/www.novartis.us/files/kisqali.pdf. Accessed September 15, 2020.
21	Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, Villanueva C, Jakobsen E, Alba E, Wist E, et al: Ribociclib with letrozole vs. letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 167:659–669. 2018.PubMed/NCBI View Article : Google Scholar
22	Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, et al: Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+/HER2-advanced breast cancer. J Natl Cancer Inst. 111:419–430. 2019.PubMed/NCBI View Article : Google Scholar